DUSP9 and neoplasm: Sorafenib’s primary mechanism involves targeting the Raf kinase to inhibit this pathway and suppress tumor growth; however, the increased expression of genes encoding DUSP9, a negative regulator of the MAPK pathway, could represent a feedback loop aimed at restoring ERK signaling, a common response in cells attempting to counteract kinase inhibitor effects.